Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | UBE2N | P61088 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907293 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL18127645 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL8746720 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1901499 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Dihydrospingosine SCHEMBL3509781 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Dihydrospingosine SCHEMBL13285654 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Dihydrospingosine SCHEMBL1905632 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21660227 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21431064 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL12330726 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2024-05-07 | — | — | US | disclosed |
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-11298412-B2 | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection | Harbins Ruhr Bioscience, Inc. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220016222-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | Harbins Ruhr Bioscience, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2021-01-21 | — | — | US | disclosed |
| US-20200268686-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | Harbins Ruhr Bioscience, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-10688065-B2 | Sphingoid compounds for prophylaxis and/or therapy of a viral infection | Harbins Ruhr Bioscience, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200113850-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | Harbins Ruhr Bioscience, Inc. | 2020-04-16 | — | — | US | disclosed |
| WO-2019185038-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | 中国医学科学院基础医学研究所 | 2019-10-03 | — | — | WO | disclosed |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-0964673-B1 | PROTECTIVE AGENTS FOR SKIN AND HAIR | TAKASAGO PERFUMERY CO LTD (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | CYP2D6 4037/4885SPHK1 2/4885LMNA 220/4885 |
| US-20200268686-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | SPHK1, SPHK2, S1PR1 | CYP2D6 4449/4885SPHK1 1/4885LMNA 835/4885 |
| US-20220016222-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | SPHK1, SPHK2, S1PR2 | CYP2D6 3331/4885SPHK1 1/4885LMNA 1095/4885 |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | CYP2D6 4264/4885SPHK1 8/4885LMNA 77/4885 |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | CYP2D6 4037/4885SPHK1 2/4885LMNA 220/4885 |
| US-10688065-B2 | Sphingoid compounds for prophylaxis and/or therapy of a viral infection | SPHK1, SPHK2, S1PR1 | CYP2D6 4449/4885SPHK1 1/4885LMNA 835/4885 |
| US-20200113850-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | SPHK1, SPHK2, S1PR1 | CYP2D6 4449/4885SPHK1 1/4885LMNA 835/4885 |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | SPTSSB, CFTR, SGMS1 | CYP2D6 4554/4885SPHK1 9/4885LMNA 1458/4885 |
| US-11298412-B2 | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection | SPHK1, SPHK2, S1PR2 | CYP2D6 3331/4885SPHK1 1/4885LMNA 1095/4885 |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | SPHK2, SPHK1, S1PR2 | CYP2D6 4037/4885SPHK1 2/4885LMNA 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.